The selective and reversible inhibition of dihydroorotate dehydrogenase (DHODH), a key mitochondrial enzyme in the de novo pyrimidine synthesis pathway, by teriflunomide has been shown to be a safe and effective strategy to treat patients with multiple sclerosis (MS). This evidence concerns the gene DHODH and myeloid sarcoma.